Comparative Pharmacology
Head-to-head clinical analysis: PRAVIGARD PAC COPACKAGED versus TICLOPIDINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRAVIGARD PAC COPACKAGED versus TICLOPIDINE HYDROCHLORIDE.
PRAVIGARD PAC (COPACKAGED) vs TICLOPIDINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pravigard PAC (copackaged) contains pravastatin, an HMG-CoA reductase inhibitor that competitively inhibits the conversion of HMG-CoA to mevalonate, reducing cholesterol synthesis, and buffered aspirin, which irreversibly acetylates cyclooxygenase (COX-1 and COX-2), inhibiting thromboxane A2 synthesis and platelet aggregation.
Ticlopidine is a thienopyridine inhibitor of platelet aggregation. It irreversibly inhibits the P2Y12 receptor on platelets, blocking ADP-mediated platelet activation and aggregation.
PRAVIGARD PAC (copackaged) is not a single drug but a copackaged product containing pravastatin and aspirin. The typical adult dose of pravastatin is 40 mg orally once daily; aspirin is 81 mg orally once daily. Both are taken together as a single daily dose.
250 mg orally twice daily
None Documented
None Documented
Pravastatin: 1.5-2 hours (terminal, clinical significance minimal due to prolonged HMG-CoA reductase inhibition); Aspirin: 15-20 minutes (acetylated form), salicylate: 2-3 hours (low dose) to 15-30 hours (high dose, due to saturable metabolism)
The terminal elimination half-life is approximately 24-36 hours after single-dose administration, prolonging to 4-5 days after multiple dosing due to time-dependent pharmacokinetics. This necessitates a loading dose regimen (e.g., 250 mg twice daily) to achieve steady-state within 2-3 days.
Pravastatin: ~20% renal, ~70% fecal (biliary); Aspirin: renal (dose-dependent, ~50-80% as salicylates, ~10-20% as salicyluric acid)
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 60% of the dose, with 23% excreted in feces as metabolites. Less than 2% of the dose is excreted unchanged in urine.
Category C
Category A/B
Antiplatelet/Statin Combination
Antiplatelet